About SBP GROUP Company

Sino Biopharmaceutical Limited ("the Company" or "Sino Biopharm") and its subsidiaries ("the Group") are a leading, innovation-driven, R&D-focused pharmaceutical group in China, with operations spanning the entire industry value chain—from R&D platforms and intelligent manufacturing to a robust sales network. Its product portfolio includes a wide range of biologics and small-molecule drugs, with strong market positions in four major therapeutic areas: oncology, liver diseases, respiratory conditions, and surgery/pain management. The Company was listed on the Hong Kong Stock Exchange in 2000 and was included in the MSCI China Index in 2013; in the Hang Seng Index in 2018; in the Hang Seng China Enterprises Index in 2019; and in the Hang Seng HSCEI Biotechnology 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index in 2020. For five consecutive years, Sino Biopharm has been ranked among the "Global Top 50 Pharmaceutical Companies" by the authoritative U.S. magazine Pharma Manager, and for three consecutive years it has been recognized as one of the "Top 50 Best Companies in Asia-Pacific" by Forbes (Asia). Sino Biopharm's subsidiaries are located in Beijing, Shanghai, Nanjing, Lianyungang, and other cities, operating multiple pharmaceutical manufacturing facilities. Since its establishment, the Company has consistently achieved outstanding results and maintained steady growth, with its core subsidiaries—Zhengda Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd.—both ranking among the top 100 Chinese pharmaceutical manufacturers for many years. Grounded in generic drug development, the Company is undergoing a comprehensive transformation toward innovation, with innovative medicines driving revenue growth and their share of total revenue increasing year by year. Its internal R&D pipeline is fueling this innovation-driven shift and continuously enhancing its technological platforms. Under the leadership of a world-class scientific team, the Company is actively advancing its internationalization strategy and striving to capture leading positions in cutting-edge global markets. Upholding the mission of "Health Technology, Bringing Warmth to More Lives," Sino Biopharm remains committed to innovation and patient-centric service, aiming to become a globally leading pharmaceutical enterprise. We look forward to sharing the fruits of development in the pharmaceutical and healthcare industries with like-minded partners, forging strong collaborations, and achieving mutual success in the future! The Group's principal subsidiaries include Zhengda Tianqing Pharmaceutical Group Co., Ltd. ("Zhengda Tianqing"), Beijing Tide Pharmaceutical Co., Ltd. ("Beijing Tide"), Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. ("Nanjing Zhengda Tianqing"), Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. ("Jiangsu Zhengda Fenghai"), Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. ("Jiangsu Zhengda Qingjiang"), and invoX Pharma Limited ("invoX"). Nanjing Zhengda Tianqing, Jiangsu Zhengda Qingjiang, and Jiangsu Zhengda Fenghai have respectively been recognized by the Jiangsu Provincial Department of Science and Technology as the "Jiangsu Provincial Engineering Research Center for Plant-Derived Chemical Drug Preparations for Oncology and Cardiovascular/Cerebrovascular Diseases," the "Engineering Research Center for Orthopedic Drug Preparations," and the "Engineering Research Center for Parenteral Nutrition." The Zhengda Tianqing R&D Center is a "Postdoctoral Research Station" accredited by the Ministry of Human Resources and Social Security of China and is also China's only "Engineering Research Center for Novel Hepatic Disease Drugs." In December 2012, Beijing Tide once again obtained GMP certification from Japan's Ministry of Health, Labour and Welfare for foreign pharmaceutical companies. Japanese pharmaceutical firms can now entrust Beijing Tide with the sterile production and export to Japan of both investigational and marketed pharmaceutical products developed in Japan.